Topic: ESOPRS 2021 ePoster sessions
Time: Sep 17, 2021 16:00 Amsterdam, Berlin, Rome, Stockholm, Vienna, 15:00 London
(plain text version here)
Association Between Semaglutide Use and Thyroid Eye Disease–Related Outcomes in Autoimmune Thyroiditis with Type 2 Diabetes
Author: Zvi Gur
ePoster Number: 116,00
Purpose
To evaluate semaglutide’s association with thyroid eye disease (TED)–related outcomes in patients with autoimmune thyroiditis and type 2 diabetes mellitus (T2DM)
Methods
Adults with thyrotoxicosis (ICD-10: E05) and T2DM were identified from the TriNetX US Collaborative Network. T2DM was defined by ICD-10 (E11.x) or two fasting glucose values ≥126 mg/dL or two HbA1c values ≥6.5% measured ≥3 months apart. The exposed cohort included patients prescribed semaglutide after December 5, 2017. Controls received non–GLP-1RA antihyperglycemic agents without prior GLP-1RA use. A 1:1 propensity score–matched cohort was constructed based on demographics, comorbidities, medications, and healthcare utilization. Five-year outcomes included: TED-related diagnoses, systemic corticosteroid use, teprotumumab use, and surgical interventions. Risk ratios (RRs) with 95% CIs were calculated.
Results
Each cohort included 23,154 propensity-matched patients (mean age 58.4 years; ~77% female). At 5 years, semaglutide users showed lower rates of TED-related diagnoses (1.46% vs 2.05%; RR, 0.71; 95% CI, 0.62–0.82), corticosteroid use (14.76% vs 18.33%; RR, 0.81; 95% CI, 0.76–0.86), and surgical interventions (0.20% vs 0.31%; RR, 0.66; 95% CI, 0.46–0.96). Teprotumumab use was similar between groups (0.09% vs 0.07%; RR, 1.25; 95% CI, 0.65–2.41).
Conclusion
Semaglutide use was associated with reduced TED-related diagnoses and treatments over 5 years in patients with autoimmune thyroiditis and T2DM. Further studies are needed to validate these findings and investigate potential mechanisms.
Additional Authors
| First name | Last name | Base Hospital / Institution |
|---|---|---|
| Tehila | Shlomov | Hadassah Medical Center |
| Rena | Pollack | Hadassah Medical Center |
| Ofira | Zloto | Sheba Medical Center |
| Itay | Nitzan | Hadassah Medical Center |
Abstract ID: 25-594
